From presentation to paper: Gender disparities in oncological research.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 06 2020
Historique:
received: 07 06 2019
revised: 22 07 2019
accepted: 07 08 2019
pubmed: 1 9 2019
medline: 8 1 2021
entrez: 1 9 2019
Statut: ppublish

Résumé

Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility of presenters. The share of women presenting at such podia is unknown. We aim to identify gender-based differences in contributions to presentations at two major oncological conferences. Abstracts presented at plenary sessions of the American Society of Clinical Oncology (ASCO) Annual Meetings and European Society for Medical Oncology (ESMO) Congresses were collected. Trend analyses were used to analyze female contribution over time. The association between presenter's sex, study outcome (positive/negative) and journals' impact factors (IFs) of subsequently published papers was assessed using Chi-square and Mann-Whitney U tests. Of 166 consecutive abstracts presented at ASCO in 2011-2018 (n = 34) and ESMO in 2008-2018 (n = 132), 21% had female presenters, all originating from Northern America (n = 17) or Europe (n = 18). The distribution of presenter's sex was similar over time (p = 0.70). Of 2,425 contributing authors to these presented abstracts, 28% were women. The proportion of female abstract authors increased over time (p < 0.05) and was higher in abstracts with female (34%) compared to male presenters (26%; p < 0.01). Presenter's sex was not associated with study outcome (p = 0.82). Median journals' IFs were lower in papers with a female first author (p < 0.05). In conclusion, there is a clear gender disparity in research presentations at two major oncological conferences, with 28% of authors and 21% of presenters of these studies being female. Lack of visibility of female presenters could impair acknowledgement for their research, opportunities in their academic career and even hamper heterogeneity in research.

Identifiants

pubmed: 31472016
doi: 10.1002/ijc.32660
pmc: PMC7187424
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3011-3021

Informations de copyright

© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Lancet. 2019 Feb 9;393(10171):560-569
pubmed: 30739691
J Evol Biol. 2013 Sep;26(9):2063-9
pubmed: 23786459
Lancet. 2019 Feb 9;393(10171):550-559
pubmed: 30739690
Lancet. 2018 May 5;391(10132):1754-1756
pubmed: 29739551
PLoS One. 2012;7(11):e49682
pubmed: 23185407
ESMO Open. 2018 Sep 21;3(6):e000422
pubmed: 30273420
mBio. 2014 Jan 07;5(1):e00846-13
pubmed: 24399856
Science. 1975 Feb 7;187(4175):398-404
pubmed: 17835295
BMJ Support Palliat Care. 2019 Jun;9(2):146-148
pubmed: 28270395
Lancet. 2019 Feb 9;393(10171):579-586
pubmed: 30739693
N Engl J Med. 2018 Jun 14;378(24):2253-2255
pubmed: 29897846
Lancet Oncol. 2019 Mar;20(3):327-329
pubmed: 30745089
J Clin Oncol. 2018 Sep 10;36(26):2680-2683
pubmed: 30004815
J Anim Sci. 1996 Nov;74(11):2843-8
pubmed: 8923199
BMJ. 2016 Mar 02;352:i847
pubmed: 26935100
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2796
pubmed: 28289199
Lancet. 2017 Dec 2;390(10111):2423-2424
pubmed: 29208297
Nat Immunol. 2017 Apr 18;18(5):475-478
pubmed: 28418385
Am Soc Clin Oncol Educ Book. 2013;:448-55
pubmed: 23714569
Lancet. 2018 Jun 30;391(10140):2602-2603
pubmed: 30070217
JAMA Intern Med. 2014 May;174(5):806-8
pubmed: 24664468
PeerJ. 2014 Oct 21;2:e627
pubmed: 25346879
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
Acad Med. 2011 Jan;86(1):43-7
pubmed: 21099390
ESMO Open. 2018 Sep 21;3(6):e000423
pubmed: 30273418
Nature. 2013 Dec 12;504(7479):211-3
pubmed: 24350369
Ann Oncol. 2014 Feb;25(2):525-8
pubmed: 24425791
Nature. 2012 Nov 22;491(7425):495
pubmed: 23189321
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):E6828-9
pubmed: 26635232
N Engl J Med. 2018 Jun 14;378(24):2255-2257
pubmed: 29897850
JAMA Oncol. 2018 Jul 1;4(7):1003-1006
pubmed: 29800044

Auteurs

Willemieke P M Dijksterhuis (WPM)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

Charlotte I Stroes (CI)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Wan-Ling Tan (WL)

Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

Suthinee Ithimakin (S)

Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Antonio Calles (A)

Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Martijn G H van Oijen (MGH)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

Rob H A Verhoeven (RHA)

Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

Jorge Barriuso (J)

Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom.
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Sjoukje F Oosting (SF)

Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Daniela Kolarevic Ivankovic (DK)

The Royal Marsden NHS Foundation Trust, London, United Kingdom.

Andrew J S Furness (AJS)

The Royal Marsden NHS Foundation Trust, London, United Kingdom.

Ivana Bozovic-Spasojevic (I)

Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.

Carlos Gomez-Roca (C)

Institut Universitaire du Cancer de Toulouse (IUCT), Toulouse, France.

Hanneke W M van Laarhoven (HWM)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH